The current "instruments and tools used to assess the value of cancer medicines may be too “blunt” to capture the true potential of future therapies and technologies to treat small patient populations, says a discussion paper released by Rare Cancers Australia. …
Latest Video
New Stories
-
Pfizer CEO says COVID-19 vaccine possible by October
July 13, 2020 - - Latest News -
Merck extends agreement with Australian company
July 13, 2020 - - Latest News -
TGA approves the first COVID-19 treatment
July 13, 2020 - - Latest News -
MSD looking for three-peat at Australian HR Awards
July 13, 2020 - - Latest News -
Industry creates antibiotic R&D fund in response to policy failure
July 13, 2020 - - Latest News -
New Code of Conduct means more media opportunities
July 10, 2020 - - Latest News -
The health minister, MSAC and the powers of a 'medieval king'
July 10, 2020 - - Latest News